Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes

Kalousek I., Brodská B., Otevřelová P., Roselová P.

. 2007 ; 18 (7) : 763-772.

Jazyk angličtina Země Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc10001019

Grantová podpora
NR7998 MZ0 CEP - Centrální evidence projektů

We have examined the ability of actinomycin D to induce apoptosis in human peripheral blood lymphocytes. Run-On assays were performed to specify the primary molecular damage, reverse transcription-PCR, Western blots and flow cytometry studies were performed to ascertain which proteins of the apoptosis machinery were affected to cause actinomycin D-induced cell death. Expression of 23 apoptosis-related genes was investigated. The down-regulation of ribosomal RNA synthesis caused by actinomycin D induced a mitochondria-dependent apoptosis. Although the expression of the majority of examined genes remained indifferent against actinomycin D activity, the cellular level of p53 protein increased, subsequently upregulating both Puma mRNA and protein. Puma-mediated mitochondrial apoptosis was accompanied by nucleolin cleavage and Bcl-2 mRNA destabilization. The stability of the cellular level of Bcl-2 protein independent of a mRNA decrease suggests that protection of Bcl-2 protein against proteasomal degradation can moderate the apoptotic process. In peripheral blood lymphocytes cultured in vitro, the apoptosis induced by a low concentration of actinomycin D (10 nmol/l) is dependent on p53 and Puma activation. This apoptotic pathway is demonstrated in peripheral blood lymphocytes for the first time. A different apoptotic pathway induced in peripheral blood lymphocytes using this drug has, however, been previously revealed by other authors. The combination of cell specificity and dose-dependent effects can likely play a decisive role in apoptosis observed in peripheral blood lymphocytes after genotoxic drug application.

000      
00000naa 2200000 a 4500
001      
bmc10001019
003      
CZ-PrNML
005      
20130820110029.0
008      
100118s2007 xxk e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kalousek, Ivan $7 xx0070918
245    10
$a Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes / $c Kalousek I., Brodská B., Otevřelová P., Roselová P.
314    __
$a Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128-20 Prague, Czech Republic. kal@uhkt.cz
520    9_
$a We have examined the ability of actinomycin D to induce apoptosis in human peripheral blood lymphocytes. Run-On assays were performed to specify the primary molecular damage, reverse transcription-PCR, Western blots and flow cytometry studies were performed to ascertain which proteins of the apoptosis machinery were affected to cause actinomycin D-induced cell death. Expression of 23 apoptosis-related genes was investigated. The down-regulation of ribosomal RNA synthesis caused by actinomycin D induced a mitochondria-dependent apoptosis. Although the expression of the majority of examined genes remained indifferent against actinomycin D activity, the cellular level of p53 protein increased, subsequently upregulating both Puma mRNA and protein. Puma-mediated mitochondrial apoptosis was accompanied by nucleolin cleavage and Bcl-2 mRNA destabilization. The stability of the cellular level of Bcl-2 protein independent of a mRNA decrease suggests that protection of Bcl-2 protein against proteasomal degradation can moderate the apoptotic process. In peripheral blood lymphocytes cultured in vitro, the apoptosis induced by a low concentration of actinomycin D (10 nmol/l) is dependent on p53 and Puma activation. This apoptotic pathway is demonstrated in peripheral blood lymphocytes for the first time. A different apoptotic pathway induced in peripheral blood lymphocytes using this drug has, however, been previously revealed by other authors. The combination of cell specificity and dose-dependent effects can likely play a decisive role in apoptosis observed in peripheral blood lymphocytes after genotoxic drug application.
650    _2
$a financování organizované $7 D005381
650    _2
$a protinádorová antibiotika $x aplikace a dávkování $x farmakologie $7 D000903
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a proteiny regulující apoptózu $x metabolismus $7 D051017
650    _2
$a western blotting $7 D015153
650    _2
$a viabilita buněk $7 D002470
650    _2
$a poškození DNA $x účinky léků $7 D004249
650    _2
$a ribozomální DNA $x účinky léků $7 D004275
650    _2
$a daktinomycin $x aplikace a dávkování $x farmakologie $7 D003609
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a down regulace $7 D015536
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a lymfocyty $x účinky léků $7 D008214
650    _2
$a mitochondrie $x metabolismus $7 D008928
650    _2
$a protoonkogenní proteiny $x metabolismus $7 D011518
650    _2
$a protoonkogenní proteiny c-bcl-2 $x metabolismus $7 D019253
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a nádorový supresorový protein p53 $x metabolismus $7 D016159
650    _2
$a upregulace $x účinky léků $7 D015854
700    1_
$a Brodská, Barbora $7 xx0161159
700    1_
$a Otevřelová, Petra. $7 xx0238631
700    1_
$a Roselová, Pavla. $7 _AN044737
773    0_
$w MED00179775 $t Anticancer Drugs $g Roč. 18, č. 7 (2007), s. 763-772 $x 0959-4973
910    __
$y 8 $a ABA008 $b x
990    __
$b ABA008 $a 20100114083259
991    __
$a 20130820110545 $b ABA008
999    __
$a ok $b bmc $g 703747 $s 566189
BAS    __
$a 3
BMC    __
$a 2007 $b 18 $c 7 $d 763-772 $m Anticancer Drugs $x MED00179775
GRA    __
$a NR7998 $p MZ0
LZP    __
$a 2010-b1/vtme

Najít záznam